TriangleHEALTH PROFESSIONAL · SOURCE READING
Rituximab
Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Nodular Lymphocyte–Predominant HL (NLPHL) / Treatment Options for NLPHL
In a phase II trial of 39 patients with previously untreated and relapsed NLPHL, most of whom had advanced-stage disease, treatment with rituximab yielded a 100% response rate. With a median follow-up of 9.8 years, the median PFS was 3.0 years for patients who received rituximab induction only and 5.6 years for patients who received rituximab induction plus rituximab maintenance.[22][Level of evidence C2] With induction only, 9 of 23 patients had disease relapse with an aggressive B-cell lymphoma.
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice